Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a leading global provider of over-the-counter (OTC) consumer goods and pharmaceutical products, delivering high-quality healthcare solutions at affordable prices. Established in 1887, Perrigo has grown from a packager of generic home remedies to a top-five global OTC manufacturer and supplier of store-brand infant formulas. Headquartered in Ireland, Perrigo operates across North America, Europe, Australia, Israel, and China.
Perrigo's diverse product portfolio includes private-label consumer health goods sold to major retailers such as Walmart, Amazon, Costco, and CVS. In addition, the company offers branded OTC products, generic extended topical prescription products, and receives royalties from the multiple sclerosis drug Tysabri®.
In recent years, Perrigo has focused on expanding its consumer self-care business. A significant milestone was the FDA approval of Opill®, the first-ever daily birth control pill available OTC in the U.S., which Perrigo began shipping in March 2024. The company's strategic initiatives also include Project Energize, a growth and efficiency program aimed at driving sustainable, value-accretive growth.
Perrigo continues to make strides in the industry, as evidenced by its financial performance and strategic partnerships. The company reported net sales of $1.1 billion for the first quarter of 2024, despite facing challenges such as inventory de-stocking at U.S. retail customers and supply chain constraints. Perrigo's leadership team, including the recent appointment of Roberto Khoury to lead the Consumer Self-Care International segment, is committed to driving innovation and expanding the company's global footprint.
For more information, visit Perrigo's website.
Perrigo reported second-quarter 2022 net sales of $1.1 billion, a 14.3% increase year-over-year, or 20.2% excluding currency impacts. Organic net sales rose 17.2%, driven by strong demand for consumer self-care products. Gross margins reported at 33.2%, with adjusted gross margins at 36.5%. Despite a reported net loss of ($0.48) per diluted share, adjusted EPS was $0.43. Perrigo raised its fiscal 2022 organic growth guidance to 9.0%-10.0% but updated adjusted EPS outlook to $2.25-$2.35 due to currency translation challenges.
Perrigo Company plc (NYSE: PRGO) declared a quarterly dividend of $0.26 per share, scheduled for payment on September 20, 2022. Shareholders on record as of September 2, 2022 will be eligible. This announcement reflects the company's commitment to providing shareholder returns amidst a challenging market environment.
Perrigo offers a range of Consumer Self-Care Products and aims to empower consumers in managing their wellness proactively.
Perrigo Company plc (NYSE: PRGO) is set to release its second quarter 2022 financial results on August 9, 2022, with a conference call scheduled for 8:30 A.M. EDT. The call will be accessible via webcast on the investor relations section of the Perrigo website. A replay will be available shortly after the call until August 16, 2022.
Perrigo is a leading provider of Consumer Self-Care Products and OTC health solutions, focusing on enhancing individual well-being.
Perrigo Company plc (NYSE: PRGO) announced that HRA Pharma has submitted an application to the FDA for the first-ever over-the-counter birth control pill, Opill®. This progestin-only pill aims to increase contraceptive access in the U.S., potentially reducing the high rate of unintended pregnancies, which number over 6.1 million annually. Major medical organizations support this initiative, underscoring its significance in reproductive health. If approved, Opill® would be the first OTC daily birth control pill available without a prescription in the U.S.
Perrigo Company plc (NYSE: PRGO) has appointed Ms. Alison Ives as Executive Vice President and Chief Scientific Officer. Ms. Ives will oversee global research and development and regulatory efforts, joining the Company’s Operating Committee. CEO Murray S. Kessler emphasized her 20 years of experience, highlighting her role in enhancing Perrigo's product portfolio, which now has over $500 million in potential revenue. Ms. Ives expressed confidence in delivering innovation with her team at Perrigo, reinforcing the company's commitment to consumer self-care.
Perrigo Company plc (NYSE: PRGO) announced that President and CEO Murray S. Kessler and CFO Eduardo Bezerra will engage in investor meetings at the Credit Suisse HALO Investment Summit in New York City on May 25, 2022, with no formal presentation planned.
Kessler is also set to virtually present at the Oppenheimer Consumer Growth and E-Commerce Conference on June 15, 2022, at 9:45 AM EDT. Interested parties can access webcasts via the Perrigo website. Perrigo is a leading provider of consumer self-care products, ranking as the largest store brand OTC player in the U.S.
Perrigo reported first quarter 2022 net sales of $1.1 billion, reflecting a 6.4% increase from the previous year, with organic growth at 9.7%. The loss per diluted share was $0.01, compared to an earnings per share of $0.02 last year. Adjusted diluted EPS dropped to $0.33 from $0.50, impacted by cost headwinds and foreign exchange fluctuations. The acquisition of HRA Pharma bolstered sales expectations, prompting an increase in fiscal 2022 net sales growth guidance to 8.5%-9.5% from 3.5%-4.5%.
Perrigo Company plc (NYSE: PRGO) has announced the succession of its executive leadership team. Eduardo Bezerra will become Chief Financial Officer on May 16, 2022, succeeding Ray Silcock, who will retire on July 15, 2022. Todd Kingma, the current EVP and General Counsel, will retire on August 31, 2022, with Kyle Hanson named as his successor, effective June 1, 2022. CEO Murray Kessler emphasized that these appointments are essential to advancing Perrigo's consumer self-care strategy and operational excellence.
Perrigo Company plc (NYSE: PRGO) declared a quarterly dividend of $0.26 per share, set for payment on June 21, 2022, to shareholders on record as of June 3, 2022. As a prominent global provider of Consumer Self-Care Products, Perrigo continues to lead in the OTC market in the U.S. and ranks among the top players in Europe. This dividend is a demonstration of the company's commitment to returning value to its shareholders and indicates confidence in its ongoing business strategy.
Perrigo Company plc (NYSE: PRGO) announced the completion of its acquisition of Héra SAS for €1.8 billion (approximately $1.9 billion) in cash on April 29, 2022. This strategic move is intended to enhance Perrigo's position in the consumer self-care market. CEO Murray Kessler highlighted that the acquisition aligns with the company's transformation plan, aiming for improved sales, earnings growth, and margin enhancement. The integration of HRA is set to expand Perrigo's geographic reach and drive innovation in self-care products.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
What products does Perrigo Company plc offer?
Where is Perrigo Company plc headquartered?
What is Project Energize?
What is Opill®?
Who are some of Perrigo's major retail partners?
What is Perrigo's focus in the healthcare market?
What recent changes have occurred in Perrigo's leadership?
How did Perrigo perform financially in Q1 2024?
What is Perrigo's approach to innovation?
How can I learn more about Perrigo Company plc?
